Pfizer records approximately $15 billion in total revenue despite declining demand for COVID-19 products
PFE Pfizer Inc
$30.03 -1.28%
View chart & analysis → - 1Pfizer's Comirnaty revenue recorded $261 million in the second quarter.
- 2A 95% decrease in Pfizer's Paxlovid revenue was observed compared to the same period last year.
- 3Pfizer has removed $7.2 billion from its cost base over the past three years.
So what's the key point?
Pfizer's revenue from COVID-19 treatments has decreased significantly compared to before. However, the company prepared for this by reducing costs by $7.2 billion over the last three years.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.